Rituximab versus cyclophosphamide for ANCA-associated vasculitis Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Cyclophosphamide
  • Granulomatosis with Polyangiitis
  • Immunosuppressive Agents
  • Microscopic Polyangiitis

abstract

  • Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the National Institutes of Allergy and Infectious Diseases, Genentech, and Biogen; ClinicalTrials.gov number, NCT00104299.)

authors

publication date

  • July 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3137658

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa0909905

PubMed ID

  • 20647199

Additional Document Info

start page

  • 221

end page

  • 32

volume

  • 363

number

  • 3